To include your compound in the COVID-19 Resource Center, submit it here.

RegeneRx ophthalmic news

RegeneRx said it will its shift clinical focus to RGN-259 to treat symptomatic dry eye syndrome from RGN-352

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE